Private company
Horizon Therapeutics Public Ltd Co
Pharmaceutical preparations company1
In its 2023 annual report the company says: “We are a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients.”75
Last updated Oct 20, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2022
74.6%Gross margin3
17.0%Operating margin3
14.4%Net margin3
12.5%Revenue growth, 20223
10.3%Return on equity3
0.50×Debt to equity3
$1.2BFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2022
- Cost of revenue25¢$920.2M
- Research and development12¢$438.0M
- Selling, general and admin42¢$1.5B
- Other costs6¢$202.9M
- Income tax0¢$5.5M
- Profit14¢$521.5M
Out of $3.6B in revenue.3
Where each dollar of operating cash went, fiscal 2022
- Capital spending5¢$64.0M
- Share buybacks20¢$250.1M
- Kept or used elsewhere75¢$943.7M
Out of $1.3B of cash from operations.3
Financial statements
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenue | $981.1M4 | $1.1B5 | $1.2B6 | $1.3B7 | $2.2B3 | $3.2B3 | $3.6B3 |
| Cost of revenue | $392.0M4 | $493.4M5 | $391.3M6 | $362.2M7 | $532.7M3 | $794.5M3 | $920.2M3 |
| Gross profit | $589.1M4 | $562.9M5 | $816.3M6 | $937.9M7 | $1.7B3 | $2.4B3 | $2.7B3 |
| Research and development | $60.7M4 | $225.0M5 | $82.8M6 | $103.2M7 | $129.0M3 | $345.3M3 | $438.0M3 |
| Selling, general and admin | $603.0M4 | $655.1M5 | $692.5M6 | $697.1M7 | $973.2M3 | $1.4B3 | $1.5B3 |
| Operating expenses | $1.9B3 | $2.1B3 | |||||
| Operating income | -$145.9M4 | -$339.5M5 | $37.9M6 | $126.6M7 | $490.0M3 | $543.1M3 | $617.4M3 |
| Interest | |||||||
| Income before tax | $462.8M3 | $526.9M3 | |||||
| Income tax | -$61.3M4 | -$108.7M5 | -$44.8M6 | -$593.2M7 | $11.8M3 | -$71.7M3 | $5.5M3 |
| Net income | -$165.6M4 | -$350.1M5 | -$38.4M6 | $573.0M7 | $389.8M3 | $534.5M3 | $521.5M3 |
| Earnings per share | -$1.034 | -$2.155 | -$0.236 | $3.137 | $1.913 | $2.373 | $2.283 |
| Earnings per share (diluted) | -$1.034 | -$2.155 | -$0.236 | $2.907 | $1.813 | $2.273 | $2.223 |
| Shares (weighted, basic) | 225.6M shares3 | 229.1M shares3 | |||||
| Shares (weighted, diluted) | 235.7M shares3 | 235.2M shares3 |
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Cash | $509.1M10 | $751.4M4 | $958.7M5 | $1.1B6 | $2.1B7 | $1.6B3 | $2.4B3 |
| Receivables | $632.8M3 | $676.3M3 | |||||
| Inventory | $225.7M3 | $169.6M3 | |||||
| Current assets | $1.0B10 | $1.3B4 | $1.5B5 | $1.7B6 | $3.1B7 | $2.8B3 | $3.7B3 |
| Property, plant and equipment | $292.3M3 | $340.5M3 | |||||
| Goodwill | $1.1B3 | $1.0B3 | |||||
| Intangible assets | $3.8B3 | $3.5B3 | |||||
| Total assets | $4.3B10 | $4.2B4 | $3.9B5 | $4.4B6 | $6.1B7 | $8.7B3 | $9.1B3 |
| Accounts payable | $30.1M3 | $155.8M3 | |||||
| Short-term debt | $16.0M3 | $16.0M3 | |||||
| Current liabilities | $605.9M10 | $795.0M4 | $708.7M5 | $723.2M6 | $875.7M7 | $886.6M3 | $949.1M3 |
| Long-term debt | $1.8B10 | $1.9B4 | $1.9B5 | $1.4B6 | $1.0B7 | $2.6B3 | $2.5B3 |
| Long-term liabilities | $3.1B3 | $3.1B3 | |||||
| Retained earnings | $318.6M3 | $590.0M3 | |||||
| Shareholders’ equity | $1.3B5 | $1.1B6 | $1.2B7 | $2.2B3 | $4.0B3 | $4.7B3 | $5.1B3 |
| Shares outstanding | 161.6M shares10 | 164.4M shares4 | 168.9M shares5 | 188.0M shares6 | 221.3M shares7 | 227.4M shares3 | 227.2M shares3 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Cash from operations | $369.5M4 | $284.3M5 | $194.5M6 | $426.3M7 | $555.7M3 | $1.0B3 | $1.3B3 |
| Depreciation and amortization | $353.8M3 | $390.4M3 | |||||
| Stock-based compensation | $219.1M3 | $182.1M3 | |||||
| Capital spending | $15.7M4 | $4.3M5 | $4.8M6 | $17.9M7 | $169.9M3 | $76.6M3 | $64.0M3 |
| Free cash flow | $353.7M | $280.0M | $189.8M | $408.5M | $385.8M | $958.7M | $1.2B |
| Cash from investing | -$3.0B3 | -$134.0M3 | |||||
| Share buybacks | $992.0K5 | $250.1M3 | |||||
| Cash from financing | $1.5B3 | -$348.0M3 |
Compare Horizon Therapeutics Public Ltd Co with another company
Corporate structure
Horizon Therapeutics Public Ltd Co sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Horizon Therapeutics Public Ltd Co
- FMR LLC Filed SC 13G/A on Horizon Therapeutics Public Ltd Co, latest Feb 9, 2023 (2 filings since Feb 9, 2022)
- VANGUARD GROUP INC Filed SC 13G/A on Horizon Therapeutics Public Ltd Co, latest Feb 9, 2023 (2 filings since Feb 10, 2022)
- Horizon Therapeutics Public Ltd Co L2
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Horizon Therapeutics Public Ltd Co reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $399.6M3 Dec 31, 2022 | $328.2M3 Dec 31, 2021 | +21.8% |
| Accumulated depreciation | $59.1M3 Dec 31, 2022 | $35.9M3 Dec 31, 2021 | +64.6% |
| Property and equipment, net | $340.5M3 Dec 31, 2022 | $292.3M3 Dec 31, 2021 | +16.5% |
| Operating-lease assets (leased space) | $99.5M3 Dec 31, 2022 | $75.7M3 Dec 31, 2021 | +31.4% |
Investments
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $1.0B3 Dec 31, 2022 | $1.1B3 Dec 31, 2021 | −5.3% |
| Intangible assets, net (excluding goodwill) | $3.5B3 Dec 31, 2022 | $3.8B3 Dec 31, 2021 | −9.5% |
| Indefinite-lived intangibles (excluding goodwill) | $810.0M3 Dec 31, 2022 | $880.0M3 Dec 31, 2021 | −8.0% |
| Finite-lived intangibles, gross | $5.5B3 Dec 31, 2022 | $5.5B3 Dec 31, 2021 | 0% |
| Accumulated amortization | $2.0B3 Dec 31, 2022 | $1.6B3 Dec 31, 2021 | +22.2% |
| Finite-lived intangibles, net | $2.7B3 Dec 31, 2022 | $3.0B3 Dec 31, 2021 | −10.0% |
Inventory
Leadership
Who has led Horizon Therapeutics Public Ltd Co, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
201520202025
- Chief executive officerTimothy P. Walbert Jul 28, 2011 to Oct 6, 202311
- ChairTimothy P. Walbert Jul 28, 2011 to Oct 6, 202311
- PresidentTimothy P. Walbert Jul 28, 2011 to Oct 6, 202311
- Chief financial officerAaron Cox May 16, 2022 to Oct 6, 202312
- Chief financial officerPaul W. Hoelscher Mar 25, 2015 to Apr 22, 202213
- Chief financial officerVaere Robert J. De Jul 28, 2011 to Oct 2, 201414
- Chief operating officerBarry Moze Mar 24, 2016 to Sep 13, 201615
Board members and other officers (39)
- Chief Commercial OfficerJacopo Leonardi May 18, 2022 to Jun 3, 202216
- Chief Accounting OfficerPatrick McIlvenny Nov 14, 2022 to Oct 6, 202317
- EVP and President, U.S.Daniel A. Camardo Aug 5, 2020 to Apr 5, 202118
- EVP, R&D & CSOKarin Rosen Nov 3, 2020 to Jan 6, 202119
- OfficerJeff Kent Feb 26, 2019 to May 12, 202120
- EVP and Chief Business OfficerAndy Pasternak Nov 5, 2019 to Oct 6, 202321
- EVP, Head of R&D and CSOShao-Lee Lin Jan 5, 2018 to Jan 23, 202022
- EVP, Technical OperationsMichael A. Desjardin Mar 3, 2017 to Oct 6, 202323
- SVP, Rheumatology Bus. UnitVikram Karnani Mar 3, 2017 to Feb 23, 202124
- SVP, Orphan Business UnitEric Mosbrooker Aug 28, 2017 to Nov 2, 201725
- EVP, Chief Human Resources OffIrina Konstantinovsky Sep 13, 2017 to Feb 23, 202126
- SVP, Corporate CommunicationsGeoffrey M. Curtis Mar 2, 2016 to Apr 2, 202127
- SVP, Commercial OperationsTimothy J. Ackerman Mar 2, 2016 to Jan 11, 201728
- EVP Global Orphan Bus. UnitDavid Happel Nov 7, 2016 to Oct 26, 201729
- EVP, Corporate Strategy and IRJohn B. Thomas May 8, 2015 to May 10, 201630
- Principal Accounting OfficerMiles W. McHugh May 8, 2015 to Jan 6, 202231
- OfficerGeorge P. Hampton Aug 7, 2015 to Apr 2, 201832
- EVP FinancePaul W. Hoelscher Jun 30, 2014 to Sep 22, 201433
- EVP, Corporate Dev't.Barry Moze Sep 22, 2014 to Jan 6, 202234
- EVP & Corporate SecretaryDavid George Kelly Nov 10, 2014 to Mar 24, 201635
- EVP, Chief Commercial OfficerJohn J. Kody Nov 25, 2014 to Nov 25, 201536
- EVP & Chief Medical OfficerJeffrey W. Sherman Jul 28, 2011 to Oct 6, 202337
- SVP, Sales & Managed CareMichael Adatto Jul 28, 2011 to Jan 3, 201338
- Board memberSusan Mahony Aug 5, 2019 to Oct 6, 202339
- Board memberPascale Witz Aug 3, 2017 to Oct 6, 202340
- Board memberThomas Watkins Apr 17, 2014 to Oct 6, 202341
- Board memberVirinder Nohria Sep 19, 2014 to May 10, 201742
- Board memberWilliam F. Daniel Sep 22, 2014 to Oct 6, 202343
- Board memberGino Santini Mar 8, 2012 to Oct 6, 202344
- Board memberHubert Birner Jul 28, 2011 to Aug 4, 201145
- Board memberJean Francois Formela Jul 28, 2011 to Mar 6, 201246
- Board memberJeff Himawan Jul 28, 2011 to Oct 6, 202347
- Board memberJeffrey W. Bird Jul 28, 2011 to Mar 13, 201448
- Board memberLouis C. Bock Jul 28, 2011 to Aug 4, 201149
- Board memberPeter Johann Jul 28, 2011 to Aug 4, 201150
- Board memberMichael G. Grey Oct 3, 2011 to Oct 6, 202351
- Board memberRonald Pauli Oct 3, 2011 to May 6, 201952
- General counselSean M. Clayton Mar 2, 2022 to Oct 6, 202353
- General counselBrian K. Beeler May 8, 2015 to Sep 17, 202154
Former names
Timeline
- Oct 6, 20238-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer55
- Oct 5, 20238-K Other events56
- Sep 12, 20238-K Other events57
- Sep 5, 20238-K Other events58
- Sep 1, 20238-K Other events59
- Aug 8, 20238-K Results of operations; Regulation FD disclosure60
- Jul 28, 20238-K Shareholder vote61
- Jun 5, 20238-K Other events62
- May 18, 20238-K Other events63
- May 3, 20238-K Results of operations64
- Apr 17, 20238-K Other events65
- Apr 10, 20238-K Other events66
- Jul 28, 2011New chief executive Timothy P. Walbert becomes CEO11
Calendar
When it reported results
- Aug 8, 2023Reported quarterly or annual results60
- May 3, 2023Reported quarterly or annual results64
- Mar 1, 2023Reported quarterly or annual results67
- Nov 2, 2022Reported quarterly or annual results68
- Oct 7, 2022Reported quarterly or annual results69
- Aug 3, 2022Reported quarterly or annual results70
- May 4, 2022Reported quarterly or annual results71
- Mar 1, 2022Reported quarterly or annual results72
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
210 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 26 major events, 137 insider forms, 4 large holders, 35 other. The latest 20:
- Oct 16, 202315-12G EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 20234 FORM 4 SUBMISSION EDGAR
- Oct 6, 2023S-8 POS EDGAR
- Oct 6, 2023S-8 POS EDGAR
- Oct 6, 2023S-8 POS EDGAR
The 210 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
49 open-market trades by officers, directors and large owners since October 2021: 1 buys and 48 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 17, 2023 | Pasternak AndyEVP, Chief Strategy Officer | Sale | 27,129 | $113.03 | $3.1M | Form 4 |
| Jan 13, 2023 | Cox AaronEVP, Chief Financial Officer | Sale | 36,148 | $113.17 | $4.1M | Form 4 |
| Jan 11, 2023 | SHERMAN JEFFREY WEVP and Chief Medical Officer | Sale | 3,368 | $113.10 | $380.9K | Form 4 |
| Jan 10, 2023 | SHERMAN JEFFREY WEVP and Chief Medical Officer | Sale | 3,368 | $113.05 | $380.8K | Form 4 |
| Jan 6, 2023 | SHERMAN JEFFREY WEVP and Chief Medical Officer | Sale | 5,187 | $113.29 | $587.6K | Form 4 |
| Dec 13, 2022 | Pasternak AndyEVP, Chief Strategy Officer | Sale | 30,169 | $112.61 | $3.4M | Form 4 |
| Dec 12, 2022 | SHERMAN JEFFREY WEVP and Chief Medical Officer | Sale | 28,352 | $111.45 | $3.2M | Form 4 |
| Aug 4, 2022 | Clayton Sean M.EVP, General Counsel | Buy | 745 | $66.67 | $49.7K | Form 4 |
| Jul 29, 2022 | Pasternak AndyEVP, Chief Strategy Officer | Sale | 4,850 | $82.57 | $400.5K | Form 4 |
| Jul 20, 2022 | Thompson Elizabeth H.Z.EVP, Research & Development | Sale | 5,917 | $85.00 | $502.9K | Form 4 |
| Jul 19, 2022 | Thompson Elizabeth H.Z.EVP, Research & Development | Sale | 90 | $85.04 | $7.7K | Form 4 |
| Jul 7, 2022 | Thompson Elizabeth H.Z.EVP, Research & Development | Sale | 82 | $85.01 | $7.0K | Form 4 |
| Jun 10, 2022 | Pasternak AndyEVP, Chief Strategy Officer | Sale | 762 | $85.36 | $65.0K | Form 4 |
| Jun 3, 2022 | Walbert Timothy PChairman, President and CEO | Sale | 25,000 | $92.34 | $2.3M | Form 4 |
| May 31, 2022 | Walbert Timothy PChairman, President and CEO | Sale | 25,000 | $92.48 | $2.3M | Form 4 |
| May 20, 2022 | Walbert Timothy PChairman, President and CEO | Sale | 25,000 | $90.00 | $2.2M | Form 4 |
| May 11, 2022 | Walbert Timothy PChairman, President and CEO | Sale | 17,600 | $90.00 | $1.6M | Form 4 |
| May 6, 2022 | Walbert Timothy PChairman, President and CEO | Sale | 7,400 | $90.86 | $672.3K | Form 4 |
| May 2, 2022 | Walbert Timothy PChairman, President and CEO | Sale | 25,000 | $96.04 | $2.4M | Form 4 |
| Apr 22, 2022 | Walbert Timothy PChairman, President and CEO | Sale | 25,000 | $106.59 | $2.7M | Form 4 |
All 49 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- FMR LLCSC 13G/A, 2 filings Feb 9, 2022 to Feb 9, 202373
- VANGUARD GROUP INCSC 13G/A, 2 filings Feb 10, 2022 to Feb 9, 202374
SEC filer profile
How Horizon Therapeutics Public Ltd Co is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARHorizon Therapeutics Public Ltd Co1
- CIK0001492426
- Filer statusLarge accelerated filer1
- Incorporated inIreland1
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- Business addressConnaught House, 1St Floor, 1 Burlington Road, Dublin, L2 41
- Phone011-353-1-772-21001
- Shares outstanding228,994,568 as of Aug 2, 20239
- Public float$18.3B as of Jun 30, 20223
- On EDGAR sinceMay 24, 20101
- Filings1,523 in all: 4 (670), 8-K (217), 3 (67), CT ORDER (62), SC 13G/A (53), 10-Q (37), DEFA14A (34), 425 (29)1
All 58 form types
CORRESP (28), UPLOAD (25), SC TO-T/A (24), SC 13G (23), DFAN14A (21), 4/A (19), S-8 (19), S-8 POS (19), 10-K (12), 424B3 (12), DEF 14A (12), SC 13D/A (12), 424B5 (10), PRE 14A (8), S-1/A (8), SC TO-C (8), 8-K/A (6), D (6), EFFECT (6), NO ACT (6), SC 13D (6), 10-K/A (5), PRRN14A (5), 10-Q/A (4), PRER14A (4), SC TO-T (4), 424B7 (3), ARS (3), DEFM14A (3), POS AM (3), PREM14A (3), 424B4 (2), 8-A12B (2), D/A (2), PREC14A (2), S-1 (2), S-3ASR (2), S-4/A (2), SEC STAFF LETTER (2), 15-12B (1), 15-12G (1), 25-NSE (1), 3/A (1), 5 (1), CERTNAS (1), DEFN14A (1), PREN14A (1), RW (1), S-3 (1), S-4 (1)
- Latest filingsAnnual report (10-K) Mar 1, 2023
Quarterly report (10-Q) Aug 8, 2023
Proxy statement (DEF 14A) Jun 30, 2023
Latest 8-K (8-K) Oct 6, 2023
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARAaron Cox, Chief financial officer
- 13
- 14
- 15SEC EDGARBarry Moze, Chief operating officer
- 16
- 17
- 18
- 19SEC EDGARKarin Rosen, EVP, R&D & CSO
- 20SEC EDGARJeff Kent, Officer
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32SEC EDGARGeorge P. Hampton, Officer
- 33SEC EDGARPaul W. Hoelscher, EVP Finance
- 34SEC EDGARBarry Moze, EVP, Corporate Dev't.
- 35
- 36
- 37
- 38
- 39SEC EDGARSusan Mahony, Board member
- 40SEC EDGARPascale Witz, Board member
- 41SEC EDGARThomas Watkins, Board member
- 42SEC EDGARVirinder Nohria, Board member
- 43SEC EDGARWilliam F. Daniel, Board member
- 44SEC EDGARGino Santini, Board member
- 45SEC EDGARHubert Birner, Board member
- 46SEC EDGARJean Francois Formela, Board member
- 47SEC EDGARJeff Himawan, Board member
- 48SEC EDGARJeffrey W. Bird, Board member
- 49SEC EDGARLouis C. Bock, Board member
- 50SEC EDGARPeter Johann, Board member
- 51SEC EDGARMichael G. Grey, Board member
- 52SEC EDGARRonald Pauli, Board member
- 53SEC EDGARSean M. Clayton, General counsel
- 54SEC EDGARBrian K. Beeler, General counsel
- 55
- 56SEC EDGAROther events
- 57SEC EDGAROther events
- 58SEC EDGAROther events
- 59SEC EDGAROther events
- 60
- 61SEC EDGARShareholder vote
- 62SEC EDGAROther events
- 63SEC EDGAROther events
- 64SEC EDGARResults of operations
- 65SEC EDGAROther events
- 66SEC EDGAROther events
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75